CF
SLNO

Corebridge Financial’s Soleno Therapeutics SLNO Stock Holding History

Corebridge Financial’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,535
Closed -$896K – 2360
2025
Q1 		$896K Sell
12,535
-185
-1% -$9.01K 0.01% 1304
2024
Q4 		$572K Buy
12,720
+357
+3% +$18.5K ﹤0.01% 1610
2024
Q3 		$624K Buy
12,363
+531
+4% +$25.4K ﹤0.01% 1616
2024
Q2 		$483K Buy
+11,832
New +$501K ﹤0.01% 1709

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Corebridge Financial's SLNO Position: Q2 2025 in Review

Corebridge Financial sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 12,535 shares — an estimated $896K sold.

Corebridge Financial first reported a position in SLNO in Q2 2024 and held it in 4 quarters. The position peaked at $896K in Q1 2025. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

  • Corebridge Financial reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 12,535 Soleno Therapeutics shares in Q2 2025, an estimated $896K.
  • Corebridge Financial first reported a position in Soleno Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Soleno Therapeutics position peaked at $896K in Q1 2025.
  • 233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.